Journal of Preventive Medicine and Public Health

  • 제55권6호
  • /
  • Pages.529-538
  • /
  • 2022
  • /
  • 1975-8375(pISSN)
  • /
  • 2233-4521(eISSN)
대한예방의학회 (The Korean Society for Preventive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Projection of Cancer Incidence and Mortality From 2020 to 2035 in the Korean Population Aged 20 Years and Older

  • Youjin, Hong (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Sangjun, Lee (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Sungji, Moon (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Soseul, Sung (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Woojin, Lim (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Kyungsik, Kim (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Seokyung, An (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Jeoungbin, Choi (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Kwang-Pil, Ko (Clinical Preventive Medicine Center, Seoul National University Bundang Hospital) ;
  • Inah, Kim (Department of Occupational and Environmental Medicine, Hanyang University College of Medicine) ;
  • Jung Eun, Lee (Department of Food and Nutrition, Seoul National University) ;
  • Sue K., Park (Department of Preventive Medicine, Seoul National University College of Medicine)
  • 투고 : 2022.03.11
  • 심사 : 2022.09.23
  • 발행 : 2022.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: This study aimed to identify the current patterns of cancer incidence and estimate the projected cancer incidence and mortality between 2020 and 2035 in Korea. Methods: Data on cancer incidence cases were extracted from the Korean Statistical Information Service from 2000 to 2017, and data on cancer-related deaths were extracted from the National Cancer Center from 2000 to 2018. Cancer cases and deaths were classified according to the International Classification of Diseases, 10th edition. For the current patterns of cancer incidence, age-standardized incidence rates (ASIRs) and age-standardized mortality rates were investigated using the 2000 mid-year estimated population aged over 20 years and older. A joinpoint regression model was used to determine the 2020 to 2035 trends in cancer. Results: Overall, cancer cases were predicted to increase from 265 299 in 2020 to 474 085 in 2035 (growth rate: 1.8%). The greatest increase in the ASIR was projected for prostate cancer among male (7.84 vs. 189.53 per 100 000 people) and breast cancer among female (34.17 vs. 238.45 per 100 000 people) from 2000 to 2035. Overall cancer deaths were projected to increase from 81 717 in 2020 to 95 845 in 2035 (average annual growth rate: 1.2%). Although most cancer mortality rates were projected to decrease, those of breast, pancreatic, and ovarian cancer among female were projected to increase until 2035. Conclusions: These up-to-date projections of cancer incidence and mortality in the Korean population may be a significant resource for implementing cancer-related regulations or developing cancer treatments.

키워드

과제정보

This study was funded partly by the Korean Foundation for Cancer Research (Grant No. CB-2017-A-2) and a grant from the Seoul National University Hospital (2021).

참고문헌

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
  2. World Health Organization. Global health estimates 2020: deaths by cause, age, sex, by country and by region, 2000-2019 [cited 2020 Jul 24]. Available from: https://www.who.int/data/stories/leading-causes-of-death-and-disability-2000-2019-avisual-summary.
  3. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51(2):417-430. https://doi.org/10.4143/crt.2019.138
  4. Jung YS, Kim YE, Park H, Oh IH, Jo MW, Ock M, et al. Measuring the burden of disease in Korea, 2008-2018. J Prev Med Public Health 2021;54(5):293-300.
  5. Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat 2020;52(2):351-358.
  6. Kweon SS. Updates on cancer epidemiology in Korea, 2018. Chonnam Med J 2018;54(2):90-100. https://doi.org/10.4068/cmj.2018.54.2.90
  7. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016;5(9):2649-2656. https://doi.org/10.1002/cam4.767
  8. Kim KW, Kim OS. Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 2020;8(2):155-173. https://doi.org/10.1007/s40980-020-00061-8
  9. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19(3):335-351.
  10. National Cancer Institute. Joinpoint trend analysis software; 2022 [cited 2022 Jan 28]. Available from: http://www.surveillance.cancer.gov/joinpoint.
  11. National Cancer Institute. Average annual percent change(AAPC) and confidence interval [cited 2022 Jul 5]. Available from: https://surveillance.cancer.gov/help/joinpoint/settingparameters/method-and-parameters-tab/apc-aapc-tau-confidence-intervals/average-annual-percent-change-aapc.
  12. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74(11):2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
  13. Ko YH, Kim SW. Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study. Investig Clin Urol 2021;62(3):282-289. https://doi.org/10.4111/icu.20200302
  14. Han HH, Park JW, Na JC, Chung BH, Kim CS, Ko WJ. Epidemiology of prostate cancer in South Korea. Prostate Int 2015;3(3):99-102. https://doi.org/10.1016/j.prnil.2015.06.003
  15. Hanf V, Hanf D. Reproduction and breast cancer risk. Breast Care (Basel) 2014;9(6):398-405. https://doi.org/10.1159/000369570
  16. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360(9328):187-195 https://doi.org/10.1016/S0140-6736(02)09454-0
  17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347(9017):1713-1727. https://doi.org/10.1016/S0140-6736(96)90806-5
  18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350(9084):1047-1059. https://doi.org/10.1016/S0140-6736(97)08233-0
  19. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13(11):1141-1151. https://doi.org/10.1016/S1470-2045(12)70425-4
  20. Park SK. Epidemiological characteristics of breast cancer in Koreans. J Korean Med Assoc 2019;62(8):424-436 (Korean). https://doi.org/10.5124/jkma.2019.62.8.424
  21. Choi E, Jun JK, Suh M, Jung KW, Park B, Lee K, et al. Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality. NPJ Breast Cancer 2021;7(1):83.
  22. Shin DW, Bae J, Ha J, Jung KW. Conditional relative survival of ovarian cancer: a Korean national cancer registry study. Front Oncol 2021;11:639839.
  23. Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet 2014;384(9957):1848.
  24. Park SH, Lee B, Lee S, Choi E, Choi EB, Yoo J, et al. A qualitative study of women's views on overdiagnosis and screening for thyroid cancer in Korea. BMC Cancer 2015;15:858.
  25. Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol 2020;8(6):468-470.
  26. Chi BH, Chang IH. The overdiagnosis of kidney cancer in Koreans and the active surveillance on small renal mass. Korean J Urol Oncol 2018;16(1):15-24 (Korean). https://doi.org/10.22465/kjuo.2018.16.1.15
  27. Byun SS, Hong SK, Lee S, Kook HR, Lee E, Kim HH, et al. The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investig Clin Urol 2016;57(1):50-57. https://doi.org/10.4111/icu.2016.57.1.50
  28. National cancer control programs in Korea. J Korean Med Sci 2007;22(Suppl):S3-S4. https://doi.org/10.3346/jkms.2007.22.S.S3
  29. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer 2016;115(9):1147-1155. https://doi.org/10.1038/bjc.2016.304
  30. Jurgens V, Ess S, Cerny T, Vounatsou P. A Bayesian generalized age-period-cohort power model for cancer projections. Stat Med 2014;33(26):4627-4636.
  31. Fekjaer H, Moller B. nordpred: fit power 5 and poisson ageperiod-cohort models for... [cited 2022 Jul 12]. Available from: https://rdrr.io/github/haraldwf/nordpred/man/nordpred.html.